Jiyue Wu

Dr. Jiyue Wu

Institute of Urology, Beijing Chaoyang Hospital, Capital Medical University, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2022 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
QBQing Bi
Qing Bi
JWJiyue Wu
Jiyue Wu
XQXue-Meng Qiu
Xue-Meng Qiu
JZJiandong Zhang
Jiandong Zhang
ZSZejia Sun
Zejia Sun
WWWei Wang
Wei Wang
Tumorigenesis is a multistage progressive oncogenic process caused by alterations in the structure and expression level of multiple genes. Normal cells are continuously endowed with new capabilities in this evolution, leading to subsequent tumor formation. Immune cells are the most important components of inflammation, which is closely associated with tumorigenesis. There is a broad consensus in cancer research that inflammation and immune response facilitate tumor progression, infiltration, and metastasis via different mechanisms; however, their protumor effects are equally important in tumorigenesis at earlier stages. Previous studies have demonstrated that during the early stages of tumorigenesis, certain immune cells can promote the formation and proliferation of premalignant cells by inducing DNA damage and repair inhibition, releasing trophic/supporting signals, promoting immune escape, and activating inflammasomes, as well as enhance the characteristics of cancer stem cells. In this review, we focus on the potential mechanisms by which immune cells can promote tumor initiation and promotion in the early stages of tumorigenesis; furthermore, we discuss the interaction of the inflammatory environment and protumor immune cells with premalignant cells and cancer stem cells, as well as the possibility of early intervention in tumor formation by targeting these cellular mechanisms.

20 May 2022 in Stem Cells International
Verified
Journal Article
Open access
PDF file
ZSZejia Sun
Zejia Sun
ZGZihao Gao
Zihao Gao
JWJiyue Wu
Jiyue Wu
XZXiang Zheng
Xiang Zheng
SJShizhao Jing
Shizhao Jing
WWWei Wang
Wei Wang
Background. MSC-derived extracellular vehicles (EVs) exhibit a protective functional role in renal ischemia/reperfusion injury (RIRI). Recent studies have revealed that mitophagy could be a potential target process in the treatment of RIRI. However, whether MSC-derived EVs are involved in the regulation of mitophagy in RIRI remains largely unknown to date. Methods. RIRI model was established in vivo in mice by subjecting them to renal ischemia/reperfusion. TCMK-1 cells were subjected to hypoxia/reoxygenation (H/R) stimulation to mimic RIRI in vitro. BMSCs and BMSC-derived EVs were isolated and identified. Renal injury was assessed using HE staining. The qPCR and western blot analyses were conducted to detect the mRNA and protein levels. Apoptosis was evaluated using the TUNEL assay and flow cytometry analysis. The EVs, autophagosomes, and mitochondria were observed using TEM. The colocalization of autophagosomes with mitochondria was confirmed through the confocal assay. The direct binding of miR-223-3p to NLRP3 was validated through the dual-luciferase assay. Results. BMSCs and BMSC-derived EVs were successfully isolated from mice and identified. The protective effect of BMSC-derived EVs against RIRI was validated both in vitro and in vivo, which was indicated by a decrease in apoptosis and inflammasome activation and an increase in mitophagy. However, this protective effect was impaired in the miR-223-3p-depleted EVs, suggesting that miR-223-3p mediated this protective effect. Further mechanistic investigation revealed that miR-223-3p suppressed inflammasome activation to enhance mitophagy by directly targeting NLRP3. Conclusion. In conclusion, the protective role of BMSC-derived EVs and exosome-delivered miR-223-3p in RIRI was validated. Exogenous miR-223-3p directly targeted NLRP3 to attenuate inflammasome activation, thereby promoting mitophagy.

4 December 2024 in Renal Failure
Verified
Journal Article
Open access
YLYuqing Li
Yuqing Li
JZJiandong Zhang
Jiandong Zhang
XQXuemeng Qiu
Xuemeng Qiu
YZYifei Zhang
Yifei Zhang
JWJiyue Wu
Jiyue Wu
WWWei Wang
Wei Wang
Methods and Results: Microarray transcriptome profiling and single-nuclei sequencing data of post-transplant fibrotic and normal grafts were obtained and used to identify RCD-related differentially expressed genes. The enrichment activity of nine RCD modalities in tissue and cells was examined using single-sample gene set enrichment analysis, and their relations with immune infiltration in renal allograft samples were also assessed. Parenchymal and non-parenchymal cells displayed heterogeneity in RCD activation. Additionally, cell–cell communication analysis was also conducted in fibrotic samples. Subsequently, weighted gene co-expression network analysis and seven machine learning algorithms were employed to identify RCD-related hub genes for renal fibrosis. A 9-gene signature, termed RCD risk score (RCDI), was constructed using the least absolute shrinkage and selection operator and multivariate Cox regression algorithms. This signature showed robust accuracy in predicting 1-, 2-, and 3-year allograft survival status (area under the curve for 1-, 2-, and 3-year were 0.900, 0.877, 0.858, respectively). Immune infiltration analysis showed a strong correlation with RCDI and the nine model genes. Finally, molecular docking simulation suggested rapamycin, tacrolimus and mycophenolate mofetil exhibit strong interactions with core RCD-related receptors. Conclusions: In summary, this study explored the activation of nine RCD pathways and their relationships with immune traits, identified potential RCD-related hub genes associated with renal fibrosis, and highlighted potential therapeutic targets for renal allograft fibrosis.

23 June 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
PCPeng Cao
Peng Cao
JWJiyue Wu
Jiyue Wu
JZJiandong Zhang
Jiandong Zhang
ZSZejia Sun
Zejia Sun
XZXiang Zheng
Xiang Zheng
WWWei Wang
Wei Wang
Background: Renal cell carcinoma (RCC) is a third most common tumor of the urinary system. Nowadays, Immunotherapy is a hot topic in the treatment of solid tumors, especially for those tumors with pre-activated immune state. Methods: In this study, we downloaded genomic and clinical data of RCC samples from The Cancer Genome Atlas (TCGA) database. Four immune-related genetic signatures were used to predict the prognosis of RCC by Cox regression analysis. Then we established a prognostic risk model consisting of the genes most related to prognosis from four signatures to value prognosis of the RCC samples via Kaplan–Meier (KM) survival analysis. An independent data from International Cancer Genome Consortium (ICGC) database were used to test the predictive stability of the model. Furthermore, we performed landscape analysis to assess the difference of gene mutant in the RCC samples from TCGA. Finally, we explored the correlation between the selected genes and the level of tumor immune infiltration via Tumor Immune Estimation Resource (TIMER) platform. Results: We used four genetic signatures to construct prognostic risk models respectively and found that each of the models could divide the RCC samples into high- and low-risk groups with significantly different prognosis, especially in advanced RCC. A comprehensive prognostic risk model was constructed by 8 candidate genes from four signatures (HLA-B, HLA-A, HLA-DRA, IDO1, TAGAP, CIITA, PRF1 and CD8B) dividing the advanced RCC samples from TCGA database into high-risk and low-risk groups with a significant difference in cancer-specific survival (CSS). The stability of the model was verified by independent data from ICGC database. And the classification efficiency of the model was stable for the samples from different subgroups. Landscape analysis showed that mutation ratios of some genes were different between two risk groups. In addition, the expression levels of the selected genes were significantly correlated with the infiltration degree of immune cells in the advanced RCC. Conclusions: Sum up, eight immune-related genes were screened in our study to construct prognostic risk model with great predictive value for the prognosis of advanced RCC, and the genes were associated with infiltrating immune cells in tumors which have potential to conduct personalized treatment for advanced RCC.

15 January 2025 in The FASEB Journal
Verified
Journal Article
Closed access
XZXiang Zheng
Xiang Zheng
DCDongshan Chen
Dongshan Chen
JWJiyue Wu
Jiyue Wu
ZGZihao Gao
Zihao Gao
MHMingcong Huang
Mingcong Huang
WWWei Wang
Wei Wang

1 January 2026 in Mediators of Inflammation
Verified
Journal Article
Open access
YZYifei Zhang
Yifei Zhang
YLYuqing Li
Yuqing Li
XQXuemeng Qiu
Xuemeng Qiu
JWJiyue Wu
Jiyue Wu
QBQing Bi
Qing Bi
WWWei Wang
Wei Wang
Background: Ischemia‐reperfusion injury (IRI) significantly impacts post‐kidney transplantation (KTx), leading to delayed graft function (DGF) and potential graft loss. Current biomarkers and therapies for DGF and graft survival are inadequate. Immune cell infiltration after renal IRI is crucial in driving inflammation and injury. Methods: To address this, this study utilized microarray and RNA‐seq datasets from the Gene Expression Omnibus (GEO) database to identify differentially expressed immune infiltration‐related genes (DE‐IRGs) in IRI patients. Machine learning (ML) algorithms pinpointed hub DE‐IRGs, aiding in predictive model development and classification of post‐KTx IRI samples into clusters and risk groups. Regulatory networks incorporating transcription factors (TFs) and microRNAs (miRNAs) were constructed using NetworkAnalyst 3.0, and predicted compounds/commonly used immunosuppressants were explored via Enrichr and molecular docking simulations. Results: Analysis revealed 47 DE‐IRGs, with hub genes (adrenomedullin [ADM], Serpin Family H Member 1 [SERPINH1], Solute carrier family 2 member 3 [SLC2A3], BCL‐2‐associated athanogene 3 [BAG3], NFKB inhibitor alpha [NFKBIA], Kruppel‐like factor 6 [KLF6], and CCAAT/enhancer‐binding protein delta [CEBPD]) linked to DGF and, in part, graft survival. Predictive models showed robust performance based on internal validation, with the DGF models achieving AUCs of 0.832 and 0.975 and graft survival models showing AUCs of 0.773, 0.742, and 0.757 for 1, 2, and 3 years, respectively. Higher immune cell infiltration correlated with adverse outcomes in cluster A or high‐risk groups. Key immune cells associated with DGF included activated CD8 T cells, activated dendritic cells (DCs), and effector memory CD4 T cells. Core regulatory TFs and miRNAs were identified, along with four core predicted compounds: acetaminophen, estradiol, valproic acid, and berbamine (which require further pharmacological validation), and three common immunosuppressants: cyclosporin A, mycophenolate mofetil (MMF), and tacrolimus. Conclusions: Our study identified potential hub genes most associated with immune cells during the post‐KTx IRI process, shedding light on the intricate interplay between genes, immune cells, and KTx outcomes.